The U.S. Food and Drug Administration on Thursday approved ziftomenib (Komzifti), a leukemia drug developed by Kura Oncology (KURA) with Japanese drugmaker Kyowa Kirin (OTCPK:KYKOF) (OTCPK:KYKOY), ...

Fintel reports that on November 24, 2025, Barclays maintained coverage of Kura Oncology (NasdaqGS:KURA) with a Overweight recommendation. Analyst Price Forecast Suggests 182.25% Upside As of November ...

At this time, I would like to welcome you to the Kura Oncology FDA approval conference call. [Operator Instructions] At this time, I would like to turn the call over to Greg Mann from Kura Oncology.

Kura Oncology has claimed FDA approval for oral menin inhibitor Komzifti for a form of acute myeloid leukaemia (AML), making it the first direct competitor to Syndax's Revuforj, which launched in the ...

Kyowa Kirin’s big bet on Kura Oncology has paid off in short order, delivering an FDA approval for a medicine to treat a subset of patients with acute myeloid leukemia. On Thursday, the FDA signed off ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Kura Oncology (KURA.O), opens new tab and Japanese partner Kyowa Kirin's (4151.T), opens new tab once-daily pill, Komzifti ...

Barclays analyst Etzer Darout maintained a Buy rating on Kura Oncology today and set a price target of $28.00. Claim 60% off TipRanks Premium for the data-backed insights and research tools you need ...

- NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients - - Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival ...

(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that ‌has ...

Kura Oncology has experienced a notable increase in its consensus analyst price target, moving from $27.18 to $31.80. This follows recent regulatory approvals that have elevated growth expectations ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...